Finance
The acquisition bolsters CCC's AI-powered SaaS platform by adding transformative AI capabilities.
The company will use the funds to drive adoption of its platform and provide capital infusion for expansion in the health markets.
The company will use the funds to increase the development of its computational platform to predict patient treatment responses and support drug research & development.
The "game-changer" acquisition will integrate the Auckland-based company's healthcare data capabilities with AI.
AI and automation revenue cycle management tools will be accessible to 160,000 physicians.
The company will fund and develop companies that focus on eight key areas in healthcare and create AI/genAI technologies that help advance those areas.
The company will use the funds to enhance its R&D strategy, advance its SEEDIT platform and boost product development.
Former HealthTap employees allege that Mohr Davidow Ventures and company leaders stripped them of equity to position the company for a profitable turnaround benefiting MDV.
The all-cash transaction will see Cross Country transition to a privately held company with its common stock no longer trading on the Nasdaq.
The company will use the funds to try and level the playing field between payers and providers.